Tiny Mitochondrial Vesicles Act as Cellular Quality Control and Messengers in Heart Health
A Circulation Research review explains how mitochondria shed small vesicles to clear damage and export mitochondria to other cells, with implications for heart disease.
Résumé
Mitochondria have more ways to maintain themselves than whole-organelle mitophagy. This review covers mitochondria-derived vesicles (MDVs), 60–150 nm packages that bud off mitochondria to remove oxidized or damaged outer membrane, inner membrane, or matrix material. MDVs mostly go to lysosomes for degradation. Some go to peroxisomes, where they help build new peroxisomes, and others go to bacteria-containing phagosomes for antimicrobial defense. When lysosomal capacity is overwhelmed, mitochondrial material can be exported in extracellular vesicles (mitoEVs). These carry mitochondrial components or whole mitochondria to other cells, which can be helpful (metabolic rescue) or harmful. The review links these processes to metabolic cooperation, immunity, tissue remodeling, ageing, and cardiovascular disease. It also surveys isolation methods and therapeutic opportunities. Much of the evidence comes from cell culture and animal models.
Résumé détaillé
Mitochondria power the heart and many other tissues, and even modest declines in their efficiency can impair function. Cells already clear fully depolarized mitochondria through PINK1/Parkin-dependent mitophagy, but this review describes a finer-grained layer of quality control: mitochondria-derived vesicles (MDVs) and, beyond the cell, mitochondrial extracellular vesicles (mitoEVs). Understanding these pathways matters because they may link organelle health to ageing, metabolic disease, immunity, and cardiovascular disease.
This is a narrative review, not a new experiment. It synthesizes cell and animal studies on how MDVs and mitoEVs form, where they travel, and what they do. MDVs are defined as cargo-selective, single- or double-membrane vesicles of roughly 60–150 nm whose formation does not depend on the autophagy or classical mitochondrial division machinery. The review describes several biogenesis routes. Outer-membrane-derived MDVs form when MIRO1/2 pull membrane protrusions along microtubules and Drp1, recruited by MID49, MID51 and MFF, cuts them off. Under oxidative stress, PINK1/Parkin help produce TOM20-negative MDVs that carry oxidized inner membrane and matrix proteins, in a process involving Snx9 and OPA1 over hours rather than the days mitophagy requires. In heat stress and inflammation, PINK1/Parkin instead suppress MDV formation, partly by promoting Snx9 degradation, which restrains mitochondrial antigen presentation. Larger (~500 nm) vesicles derived from the inner membrane (VDIMs) form through VDAC1 pores, lysosomal contact, TRPML1 calcium release and ESCRT-mediated scission. Metabolites such as β-hydroxybutyrate (via Snx9 modification) and fumarate also promote MDV formation, as do glucose deprivation, low-dose carbon monoxide, and LKB1/Rab9 signaling in endothelial cells. MDV abundance in the heart appears to vary by sex and time of day, though a neurodegeneration cohort showed no sex difference.
After budding, most MDVs travel to lysosomes through machinery involving Syntaxin-17, SNAP29, VAMP7, Tollip, Rab7 and VPS35. Others go to peroxisomes: MAPL-positive MDVs depend on the retromer (VPS35/VPS26), and MARCH5 drives mitochondrial vesicles containing PEX3 that contribute to de novo peroxisome formation. During Staphylococcus aureus infection, macrophage MDVs carrying SOD2 fuse with phagosomes and help kill bacteria. When lysosomal capacity is exceeded, MDVs can be routed into multivesicular bodies and released as exosomes or microvesicles.
The review then moves to mitoEVs, which can carry whole mitochondria or mitochondrial components. Early work showed that mitochondria-containing vesicles from mesenchymal stem cells or fibroblasts rescued respiration and ATP production in mtDNA-deficient cells. Subtypes include microvesicles (for example, ARRDC1-dependent, LC3-positive MSC vesicles), exosomes (adipocytes release damaged mitochondrial components this way, with only MDVs of about 30–150 nm fitting), exophers, migrasomes, mitophers and mitolysosomes. Transfer to recipient cells can occur alongside tunnelling nanotubes and gap junctions. The abstract states that mitoEVs have both pathogenic and beneficial roles in cardiovascular disease and have therapeutic potential.
The main implication is that vesicle-based mitochondrial quality control is a distinct, targetable layer of cell homeostasis. Major caveats are that the underlying evidence is largely preclinical, MDVs are hard to label and quantify, and many mechanisms (such as exactly how PINK1/Parkin regulate MDV formation) remain unresolved. The provided text ends partway through the mitoEV section, so the cardiovascular disease, ageing, isolation and therapeutic sections could not be summarized in detail.
Principales conclusions
- MDVs are cargo-selective vesicles (~60–150 nm) that remove oxidized mitochondrial components without requiring full mitophagy or the autophagy and division machinery.
- PINK1/Parkin promote MDV formation under oxidative stress within hours but suppress it under heat stress and inflammation, partly via Snx9 degradation.
- Most MDVs go to lysosomes, but some feed peroxisome biogenesis (MAPL, MARCH5, PEX3) or deliver SOD2 to bacteria-containing phagosomes.
- Metabolites such as β-hydroxybutyrate and fumarate, plus glucose deprivation and LKB1/Rab9 signaling, promote MDV generation.
- MitoEVs export mitochondria or components as microvesicles, exosomes and exophers, and can rescue respiration in recipient cells.
Méthodologie
Narrative review synthesizing preclinical studies (cell lines, primary cells, animal models) and some human cohort data on MDV and mitoEV biogenesis, trafficking, isolation and disease roles. It follows no systematic search or meta-analytic protocol. The supplied text is truncated partway through the mitoEV biogenesis section.
Limites de l'étude
Most evidence comes from in vitro and animal studies, and MDVs are small, heterogeneous and technically hard to label and quantify, so mechanisms and sex differences remain uncertain. As a narrative review it may reflect selection bias. The provided full text cuts off before the sections on cardiovascular disease, ageing, isolation protocols and therapeutics, so those are covered only through the abstract.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :